CoChat

Protein-Protein Interactions and Aggregation Inhibitors in Alzheimer’s Disease

The DOI matches its Crossref record; 285 of the 285 references it cites were found in a registry or an index.

Abstract

Background: Alzheimer’s Disease (AD), a multifaceted disorder, involves complex pathophysiology and plethora of protein-protein interactions. Thus such interactions can be exploited to develop anti-AD drugs. Objective: The interaction of dynamin-related protein 1, cellular prion protein, phosphoprotein phosphatase 2A and Mint 2 with amyloid β, etc., studied recently, may have critical role in progression of the disease. Our objective has been to review such studies and their implications in design and development of drugs against the Alzheimer’s disease. Methods: Such studies have been reviewed and critically assessed. Results: Review has led to show how such studies are useful to develop anti-AD drugs. Conclusion: There are several PPIs which are current topics of research including Drp1, Aβ interactions with various targets including PrPC, Fyn kinase, NMDAR and mGluR5 and interaction of Mint2 with PDZ domain, etc., and thus have potential role in neurodegeneration and AD. Finally, the multi-targeted approach in AD may be fruitful and opens a new vista for identification and targeting of PPIs in various cellular pathways to find a cure for the disease.

Overview

Integrity signals

Registry

Crossref · 10.2174/1568026619666190304153353

Cites

285 of 285 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

2 retracted

Show all 285 references

Research works printed but not linked: 6

  1. Mannhold R, Kubinyi H, Folkers G.
  2. Watkins AM.
  3. Berg T.
  4. Kojro E, Fahrenholz F. The non-amyloidogenic pathway In:
  5. Cumming J, Babu S, Huang Y, Carrol C, Chen X, Favreau L, Greenlee W, Guo T, Kennedy M, Kuvelkar R, Le T, Li G, McHugh N, Orth P, Ozgur L, Parker E, Saionz K, Stamford A, Strickland C, Tadesse D, Voigt J, Zhang L, Zhang Q. Piperazine sulfonamide BACE1 inhibitors: design, synthesis, and characterization. · DOI
  6. Aydın A, Akkurt M, Alptüzün V, Büyükgüngör O, Holzgrabe U, Radacki K. 4-[(2E)-2-(4-Chloro-benzyl-idene)hydrazinyl-idene]-1-methyl-1,4-dihydro-pyridine monohydrate.

Cited by

See all 31

Metadata

Authors
Ganeshpurkar, A., Swetha, R., Kumar, D., Gangaram, G. P., Singh, R., Gutti, G., Jana, S., Kumar, D., Kumar, A., & Singh, S. K.
Affiliations
  • Indian Institute of Technology BHU (IN)
  • Pharmaceutical Chemistry Research Laboratory, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi 221005, India
Corresponding author
Singh, Sushil K.
Venue
Current Topics in Medicinal Chemistry
Published
2019-05-31
Volume
19
Issue
7
Pages
501-533
ISSN
1568-0266 (ISSN-L)
OpenAlex
W2920856048
Cited by
30
References
284
Citations by year
2025: 2 · 2024: 5 · 2023: 5 · 2022: 2 · 2021: 7 · 2020: 4 · 2019: 5
FWCI
0.53
Type
journal article
Language
en
Open access
closed
Locations
  • Current Topics in Medicinal Chemistry (publishedVersion)
  • PubMed (publishedVersion)
Funders
Department of Biotechnology (DBT), New Delhi, India (BT/PR9624/MED/30/1253/2013)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
Alzheimer's disease, protein-protein interaction, aggregation inhibitors, amyloid-beta, Drp1, cellular prion protein, Fyn, NMDA receptor, mGluR5, PDZ domain, anti-Alzheimer agents
MeSH terms
Drug Development, Alzheimer Disease, Humans, Protein Binding, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Amyloid Precursor Protein Secretases, Protein Interaction Domains and Motifs, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Protein-Protein Interactions and Aggregation Inhibitors in Alzheimer’s Disease. https://app.cochat.ai/papers/10.2174/1568026619666190304153353
The paper
Ganeshpurkar, A., Swetha, R., Kumar, D., Gangaram, G. P., Singh, R., Gutti, G., Jana, S., Kumar, D., Kumar, A., & Singh, S. K. (2019). Protein-Protein Interactions and Aggregation Inhibitors in Alzheimer’s Disease. Current Topics in Medicinal Chemistry. https://doi.org/10.2174/1568026619666190304153353

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.